Advertisement

Ads Placeholder
Loading...

Stemcell United Limited

SCU.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.003
$0.00(0.00%)
Australian Market opens in 60h 25m

Stemcell United Limited Fundamental Analysis

Stemcell United Limited (SCU.AX) shows weak financial fundamentals with a PE ratio of -0.94, profit margin of -24.67%, and ROE of -82.38%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position18.70%
PEG Ratio-0.01
Current Ratio2.11

Areas of Concern

ROE-82.38%
Operating Margin-19.04%
We analyze SCU.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -93.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-93.7/100

We analyze SCU.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

SCU.AX struggles to generate sufficient returns from assets.

ROA > 10%
-46.40%

Valuation Score

Excellent

SCU.AX trades at attractive valuation levels.

PE < 25
-0.94
PEG Ratio < 2
-0.01

Growth Score

Weak

SCU.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

SCU.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.41
Current Ratio > 1
2.11

Profitability Score

Weak

SCU.AX struggles to sustain strong margins.

ROE > 15%
-8237.75%
Net Margin ≥ 15%
-24.67%
Positive Free Cash Flow
No

Key Financial Metrics

Is SCU.AX Expensive or Cheap?

P/E Ratio

SCU.AX trades at -0.94 times earnings. This suggests potential undervaluation.

-0.94

PEG Ratio

When adjusting for growth, SCU.AX's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Stemcell United Limited at 1.10 times its book value. This may indicate undervaluation.

1.10

EV/EBITDA

Enterprise value stands at -1.29 times EBITDA. This is generally considered low.

-1.29

How Well Does SCU.AX Make Money?

Net Profit Margin

For every $100 in sales, Stemcell United Limited keeps $-24.67 as profit after all expenses.

-24.67%

Operating Margin

Core operations generate -19.04 in profit for every $100 in revenue, before interest and taxes.

-19.04%

ROE

Management delivers $-82.38 in profit for every $100 of shareholder equity.

-82.38%

ROA

Stemcell United Limited generates $-46.40 in profit for every $100 in assets, demonstrating efficient asset deployment.

-46.40%

Following the Money - Real Cash Generation

Operating Cash Flow

Stemcell United Limited generates limited operating cash flow of $-3.02M, signaling weaker underlying cash strength.

$-3.02M

Free Cash Flow

Stemcell United Limited generates weak or negative free cash flow of $-4.08M, restricting financial flexibility.

$-4.08M

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

SCU.AX converts -91.70% of its market value into free cash.

-91.70%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.94

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.10

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.27

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.41

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.11

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.82

vs 25 benchmark

ROA

Return on assets percentage

-0.46

vs 25 benchmark

ROCE

Return on capital employed

-0.57

vs 25 benchmark

How SCU.AX Stacks Against Its Sector Peers

MetricSCU.AX ValueSector AveragePerformance
P/E Ratio-0.9428.54 Better (Cheaper)
ROE-82.38%738.00% Weak
Net Margin-24.67%-43982.00% (disorted) Weak
Debt/Equity0.410.34 Weak (High Leverage)
Current Ratio2.112806.01 Strong Liquidity
ROA-46.40%-14624.00% (disorted) Weak

SCU.AX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stemcell United Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ